首页> 外国专利> N-CADHERIN AND FGFR1 AND/OR FGFR4 FOR USE IN PREDICTING THE RESPONSE OF PATIENTS TO A LUNG CANCER TREATMENT AND METHOD AND KIT BASED ON SAID USE

N-CADHERIN AND FGFR1 AND/OR FGFR4 FOR USE IN PREDICTING THE RESPONSE OF PATIENTS TO A LUNG CANCER TREATMENT AND METHOD AND KIT BASED ON SAID USE

机译:N-Cadherin和FGFR1和/或FGFR4用于预测患者对肺癌处理和方法和试剂盒的反应,基于所述使用

摘要

The present invention describes a method for predicting the response of a subject suffering from lung cancer to treatment with FGFR inhibitors. The relationship between the expression of the biomarkers and the treatment response allows the subjects to be classified as responsive or unresponsive to the treatment, which facilitates the therapeutic decision-making of the attending clinician. The present invention also describes the biomarkers N-cadherin, FGFR1 and FGFR4, how to analyse them and how to interpret the results obtained, in order to administer FGFR inhibitors only to the subjects that are responsive to the treatment, thereby optimising the same, which allows the unresponsive subjects to be treated with alternative therapies to the FGFR inhibitors.
机译:本发明描述了一种预测患有肺癌的受试者的响应以与FGFR抑制剂治疗的方法。生物标志物的表达与治疗反应之间的关系允许受试者被归类为对治疗的响应或反应诊断,这促进了参加临床医生的治疗决策。本发明还描述了生物标志物N-cadherin,FGFR1和FGFR4,如何分析它们以及如何解释所获得的结果,以便仅向响应于治疗的受试者施用FGFR抑制剂,从而优化相同的对象允许将无响应的受试者用替代疗法治疗FGFR抑制剂。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号